Related Experiment Video
Updated: Jul 18, 2026

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow
B Gesundheit1, M Y Shapira, A Ackerstein
1Department of Bone Marrow Transplantation, Hadassah Hebrew University Medical Center, Jerusalem, Israel. gesund@hadassah.org.il
Abstract:
Multiple myeloma (MM) is an incurable progressive disease. Many therapeutic options are available to delay progression, including autologous and allogeneic bone marrow transplantation. At advanced stages, MM is often refractory to treatment. We report a heavily pretreated patient with graft-versus-host disease after bone marrow transplantations, treated at a terminal stage with a modified protocol for arsenic trioxide (ATO). This patient with poor clinical status tolerated the treatment very well. He had a remarkable clinical response and achieved complete remission. The mechanisms of ATO are presented and the potential role of ATO for MM is discussed.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Treatment Resistant Cancers
Treatment Resistent Cancers